Polypharmacy, drug-drug interactions and the pharmacology of ageing – Dr. Marta Boffito Welcome to your Polypharmacy, drug-drug interactions and the pharmacology of ageing – Dr. Marta Boffito Which of the following statements is true?a. Biktarvy is metabolised by cytochrome P450b. Bictegravir is never a victim of drug-drug interactionsc. Bictegravir is metabolised by approximately 50% by cytochrome P450d. Raltegravir and bictegravir are identical drugs Which of the following statements is true?Raltegravir is:-a. A strong perpetrator of drug-drug interactionsb. A novel non nucleoside reverse transcriptase inhibitorc. A victim of the interaction with rifampicind. Dosed at 400mg once daily Which of the following statements is false>a. Unboosted integrase inhibitors are characterised by a low potential for drug-drug interactionsb. Elvitegravir/cobicistat is a victim of the interaction with rifampicinc. Biktarvy should not be co-administered with rifabutind. Raltegravir is mainly metabolised by UGT1A1 (UDP-glucuronosyltransferase) Which of the following statements is true?On the http://www.hiv-druginteractions.org website:-a. The red symbol means 'no clinically significant drug interaction expected'b. The amber (orange) symbol means 'potential interaction - may require close monitoring alteration of drug dosage or timing of administration'c. There are no green symbolsd. The website does not exist Time is Up!